New hope for rare bone and skin condition: etanercept trial launches
NCT ID NCT06011889
First seen Apr 14, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tests if etanercept, a drug that blocks inflammation, can reduce pain and disease activity in adults with SAPHO syndrome—a rare condition causing bone and skin issues. Participants must have tried standard treatments like NSAIDs without enough relief. The trial compares etanercept to a placebo over 12 weeks to see if it helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAPHO SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centrum Wsparcia Badań Klinicznych
RECRUITINGWarsaw, Masovian Voivodeship, 02-637, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.